Torrent Pharma to acquire controlling stake in JB Pharma from KKR
Torrent Pharmaceuticals and global investment firm KKR (KKR) announced that Torrent has entered into definitive agreements to acquire controlling stake in J. B. Chemicals and Pharmaceuticals, or JB Pharma, from KKR at an Equity Valuation of INR 25,689 crores, followed by a merger of the two entities. The transaction marks a significant step in Torrent's ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO capabilities. The transaction will be executed in 2 phases: Acquisition of 46.39% equity stake through a Share Purchase Agreement at a consideration of INR 11,917 crores followed by a mandatory open offer to acquire up to 26% of JB Pharma shares from public shareholders at an open offer price of INR 1,639.18 per share. In addition to the above, Torrent has also expressed its intent to acquire up to 2.80% of equity shares from certain employees of JB Pharma at the same price per share as KKR. Merger between Torrent and JB Pharma through a scheme of arrangement. As per the approval given by the Board of Directors of both companies, upon merger of JB Pharma with Torrent, every shareholder holding 100 shares in JB Pharma shall receive 51 shares of Torrent.
Don't Miss TipRanks' Half Year Sale
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Assura Group Rejects KKR & Co. Inc. (KKR) Takeover Bid in Favor of Competitor $2.4 Billion Offer
KKR & Co. Inc. (NYSE:KKR) one of the best stocks in a . An iconic financial building in the background, with silhouettes of busy bankers walking past in the foreground. Recently, on June 24, 2025, Assura Group, based in the UK, rejected KKR & Co. Inc. (NYSE:KKR)'s final bid of $2.3 billion in favor of a competitive offer of $2.4 billion from Primary Health Properties (PHP). The decision materialized after months of competitive bidding, eventually leading to the Assura board's decision to take up PHP's offer, considering it more favorable for shareholders. KKR & Co. Inc. (NYSE:KKR) was ultimately outbid, despite having previously secured a tentative agreement. This represents a significant setback for KKR in its efforts to acquire Assura. This decision is a reflection of the company's strategic ambition as well as industry competition. Regardless of the setback, analysts remain positive about KKR's fundamentals, given 12 'Buy' ratings and a consensus price target suggesting over 16% upside. The company is focused on targeted acquisitions and growth-inducing investments as a private equity and real estate investment firm, leading to a strong position in a growth stock portfolio. While we acknowledge the potential of KKR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 10 Best Marketing Stocks to Buy Right Now and 10 Best Cybersecurity Stocks to Invest in Under $20. Disclosure: None
Wall Street Journal
7 hours ago
- Wall Street Journal
KKR to Sell Stake in Indian Pharma Company for $1.4 Billion
Private-equity firm KKR has agreed to sell its entire stake in India-listed J.B. Chemicals & Pharmaceuticals for $1.4 billion. Under the deal, KKR will sell its 46.39% stake to Torrent Pharmaceuticals 500420 3.68%increase; green up pointing triangle, the private-equity firm said late Sunday. The two pharmaceutical firms will then merge through a scheme of arrangement.
Business Insider
7 hours ago
- Business Insider
Torrent Pharma to acquire controlling stake in JB Pharma from KKR
Torrent Pharmaceuticals and global investment firm KKR (KKR) announced that Torrent has entered into definitive agreements to acquire controlling stake in J. B. Chemicals and Pharmaceuticals, or JB Pharma, from KKR at an Equity Valuation of INR 25,689 crores, followed by a merger of the two entities. The transaction marks a significant step in Torrent's ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO capabilities. The transaction will be executed in 2 phases: Acquisition of 46.39% equity stake through a Share Purchase Agreement at a consideration of INR 11,917 crores followed by a mandatory open offer to acquire up to 26% of JB Pharma shares from public shareholders at an open offer price of INR 1,639.18 per share. In addition to the above, Torrent has also expressed its intent to acquire up to 2.80% of equity shares from certain employees of JB Pharma at the same price per share as KKR. Merger between Torrent and JB Pharma through a scheme of arrangement. As per the approval given by the Board of Directors of both companies, upon merger of JB Pharma with Torrent, every shareholder holding 100 shares in JB Pharma shall receive 51 shares of Torrent. Don't Miss TipRanks' Half Year Sale
